WuXi Opens Cell Therapy Manufacturing Facility in Philadelphia

WuXi AppTec, a China-US CRO/CMO, officially opened a 150,000-square-foot biomanufacturing facility in Philadelphia. This facility will produce viral vector-based cell therapy products such as chimeric antigen receptor T cell (CAR T cell) therapies. The new plant will also expand production of viral vector manufacturing to support gene therapy programs, including large-scale production in 2,000L single-use bioreactors. In Philadelphia, WuXi is already operating two smaller plants. Together, WuXi says the three facilities position the company as a single-source for process development, clinical and commercial cGMP manufacturing, and analytical testing for cell and gene therapy products. More details....

Share this with colleagues: